Your browser doesn't support javascript.
Anti-CD20 monoclonal antibodies inhibit seropositive response to Covid-19 vaccination in non-Hodgkin lymphoma patients within 6 months after treatment.
Tvito, Ariella; Ronson, Aaron; Ghosheh, Renan; Kharit, Mira; Ashkenazi, Jakob; Magen, Sophie; Broide, Ellen; Benayoun, Emmanuel; Rowe, Jacob M; Ofran, Yishai; Ganzel, Chezi.
  • Tvito A; Department of Hematology, Shaare Zedek Medical Center, Jerusalem, Israel. Electronic address: ariellat@szmc.org.il.
  • Ronson A; Department of Hematology, Shaare Zedek Medical Center, Jerusalem, Israel.
  • Ghosheh R; Department of Hematology, Shaare Zedek Medical Center, Jerusalem, Israel.
  • Kharit M; Department of Hematology, Shaare Zedek Medical Center, Jerusalem, Israel.
  • Ashkenazi J; Department of Hematology, Shaare Zedek Medical Center, Jerusalem, Israel.
  • Magen S; Immunology Laboratories, Shaare Zedek Medical Center, Jerusalem, Israel.
  • Broide E; Immunology Laboratories, Shaare Zedek Medical Center, Jerusalem, Israel.
  • Benayoun E; Immunology Laboratories, Shaare Zedek Medical Center, Jerusalem, Israel.
  • Rowe JM; Department of Hematology, Shaare Zedek Medical Center, Jerusalem, Israel.
  • Ofran Y; Department of Hematology, Shaare Zedek Medical Center, Jerusalem, Israel.
  • Ganzel C; Department of Hematology, Shaare Zedek Medical Center, Jerusalem, Israel.
Exp Hematol ; 107: 20-23, 2022 03.
Article in English | MEDLINE | ID: covidwho-1587768
ABSTRACT
The Covid-19 pandemic has caused millions of deaths worldwide. Although vaccines have been developed, patients on immunosuppressive therapy are less likely to respond. This study was aimed at investigating the efficacy of a Covid-19 vaccine (Pfizer-BioNTech) in patients with non-Hodgkin lymphoma treated with anti-CD20 monoclonal antibodies. Only 1 of 28 lymphoma patients (3.6%) developed a seropositive response, compared with 100% (28/28) of the healthy volunteers. The low levels of CD19+ lymphocytes among the lymphoma patients suggest that anti-CD20 treatment prevents the seropositive response to the vaccine. An additional vaccination might be indicated in these patients once B cells are repopulated.
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Lymphoma, Non-Hodgkin / COVID-19 Topics: Vaccines / Variants Limits: Humans Language: English Journal: Exp Hematol Year: 2022 Document Type: Article

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Lymphoma, Non-Hodgkin / COVID-19 Topics: Vaccines / Variants Limits: Humans Language: English Journal: Exp Hematol Year: 2022 Document Type: Article